Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
The DZNE is dedicated to understanding, decoding causes, and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, ALS, and others. It conducts extensive research, clinical studies, and collaborates internationally to advance knowledge and treatment options for neurodegenerative disorders. The organization also actively engages in public communication, education, and societal issues related to neurodegeneration, including campaigns to reduce stigma and increase awareness.
Industries
Nr. of Employees
Very Large (1000+)
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
Products
Mobile cognitive assessment application
Smartphone/tablet application for repeated cognitive tests and health questionnaires to collect anonymized longitudinal cognitive data from lay participants.
Vaccine research project targeting repeat-derived proteins
Research project developing and testing an immunotherapeutic approach targeting pathogenic repeat-derived proteins associated with a mutation-driven neurodegenerative disorder.
Research podcast series
Monthly podcast featuring interviews with researchers discussing scientific topics and personal perspectives related to neurodegenerative disease research.
Mobile cognitive assessment application
Smartphone/tablet application for repeated cognitive tests and health questionnaires to collect anonymized longitudinal cognitive data from lay participants.
Vaccine research project targeting repeat-derived proteins
Research project developing and testing an immunotherapeutic approach targeting pathogenic repeat-derived proteins associated with a mutation-driven neurodegenerative disorder.
Research podcast series
Monthly podcast featuring interviews with researchers discussing scientific topics and personal perspectives related to neurodegenerative disease research.
Services
Recruitment support, public study listings and an information line for prospective participants and referring clinicians.
On-site MRI and PET imaging services for diagnostic confirmation, imaging biomarker acquisition and interventional study safety monitoring.
Collection, curation and distribution of human brain tissue and associated biospecimens for research use.
Provision of methodological and technical support including assay development, laboratory techniques and data analysis for internal and external research projects.
Media relations support, provision of press contacts, interview facilitation, coordination of filming and preparation of background information for journalists.
Organization and delivery of public lectures, Music & Brain events, lecture series and scientific symposia to support dissemination and interdisciplinary exchange.
Recruitment support, public study listings and an information line for prospective participants and referring clinicians.
On-site MRI and PET imaging services for diagnostic confirmation, imaging biomarker acquisition and interventional study safety monitoring.
Collection, curation and distribution of human brain tissue and associated biospecimens for research use.
Provision of methodological and technical support including assay development, laboratory techniques and data analysis for internal and external research projects.
Media relations support, provision of press contacts, interview facilitation, coordination of filming and preparation of background information for journalists.
Organization and delivery of public lectures, Music & Brain events, lecture series and scientific symposia to support dissemination and interdisciplinary exchange.
Expertise Areas
- Clinical trial management for neurodegenerative diseases
- Biomarker discovery and validation (blood, CSF, imaging)
- Human neuroimaging and image-based safety monitoring
- Genetic and molecular neuroscience (mutation-focused research)
Key Technologies
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Antisense oligonucleotides
- Monoclonal antibody therapeutics
News & Updates
A new drug, Lecanemab, has been approved for early-stage Alzheimer's treatment, aiming to slow disease progression.
A citizen science project using a mobile app to study factors affecting memory and cognition in daily life.
Research using smartphone apps to investigate memory and factors influencing it, involving the public.
Prof. Lars Lannfelt received an award for his pioneering work on the Alzheimer's drug Lecanemab.
A research project combining AI and brain data aims to improve stroke treatment.
Research on early blood markers for inherited Alzheimer disease.
A new drug, Lecanemab, has been approved for early-stage Alzheimer's treatment, aiming to slow disease progression.
A citizen science project using a mobile app to study factors affecting memory and cognition in daily life.
Research using smartphone apps to investigate memory and factors influencing it, involving the public.
Prof. Lars Lannfelt received an award for his pioneering work on the Alzheimer's drug Lecanemab.
A research project combining AI and brain data aims to improve stroke treatment.
Research on early blood markers for inherited Alzheimer disease.